New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Bristol Myers Squibb Company

BMY

Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue
+6.93%
EPS
−2.78%
Free cash flow
−36.0%
Total debt
−12.5%

Quarter to September 2026, against a year earlier

59.46 1.12 +1.92%
Market cap
$119.3B
P/E
12.9×
Fwd P/E FY26e
12.0×
Dividend yield
4.32%
F-score
8/9
ROIC
13.2%
Net debt / EBITDA
2.6×
Payout ratio
0.6×

Revenue to profit Fiscal 2025, year to Dec 31, 2025

Of every $100 of revenue, $14.64 was left as profit. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue48.2100.0%
Cost of revenue−13.9−28.9%
Gross profit34.371.1%
Research & development−10.0−20.6%
Selling, general & admin−7.3−15.1%
Other operating costs−7.7−16.0%
Operating income9.319.4%
Income tax−2.3−4.7%
Net income7.114.6%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, ten years
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue$19.4B$20.8B$22.6B$26.1B$42.5B$46.4B$46.2B$45.0B$48.3B$48.2B
Operating income$5.9B$5.1B$6.0B$5.0B−$6.9B$8.1B$7.7B$8.4B−$8.4B$9.3B
Net income$4.5B$975M$4.9B$3.5B−$9.0B$7.0B$6.3B$8.0B−$8.9B$7.1B
Net margin (right axis)23.2%4.7%21.9%13.2%−21.2%15.1%13.7%17.9%−18.5%14.6%
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
48,194.00 48,300.00 45,006.00 46,159.00 46,385.00 42,518.00 26,145.00 22,561.00 20,776.00 19,427.00
Revenue Growth
(0.22%) 7.32% (2.50%) (0.49%) 9.09% 62.62% 15.89% 8.59% 6.94% 17.31%
Gross Profit
34,258.00 34,332.00 34,313.00 36,022.00 36,445.00 30,745.00 18,067.00 16,094.00 14,762.00 14,458.00
Operating Income
9,328.00 (8,379.00) 8,440.00 7,713.00 8,098.00 (6,871.00) 4,975.00 5,968.00 5,131.00 5,915.00
EBT
9,328.00 (8,379.00) 8,440.00 7,713.00 8,098.00 (6,871.00) 4,975.00 5,968.00 5,131.00 5,915.00
Income after Tax
7,056.00 (8,933.00) 8,040.00 6,345.00 7,014.00 (8,995.00) 3,460.00 4,947.00 975.00 4,507.00
Net Income Common
7,054.00 (8,948.00) 8,025.00 6,327.00 6,994.00 (9,015.00) 3,439.00 4,920.00 1,007.00 4,457.00
EPS (Diluted)
3.46 (4.41) 3.86 2.95 3.12 (3.99) 2.01 3.03 0.61 2.65
Shares (Diluted, Weighted)
2,039.00 2,027.00 2,078.00 2,146.00 2,245.00 2,258.00 1,712.00 1,637.00 1,652.00 1,680.00
Gross Margin
71.08% 71.08% 76.24% 78.04% 78.57% 72.31% 69.10% 71.34% 71.05% 74.42%
EBIT Margin
19.36% (17.35%) 18.75% 16.71% 17.46% (16.16%) 19.03% 26.45% 24.70% 30.45%
Net Profit Margin
14.64% (18.53%) 17.83% 13.71% 15.08% (21.20%) 13.15% 21.81% 4.85% 22.94%
Free Cash Flow Margin
26.65% 28.87% 28.11% 25.88% 32.84% 31.28% 28.20% 27.10% 20.31% 9.49%
EBITDA
13,339.00 1,221.00 18,200.00 17,989.00 18,784.00 3,509.00 6,721.00 6,605.00 5,920.00 6,297.00
EBIT
9,328.00 (8,379.00) 8,440.00 7,713.00 8,098.00 (6,871.00) 4,975.00 5,968.00 5,131.00 5,915.00

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026